Shares of Relypsa (NASDAQ:RLYP) saw an erosion of -0.55 points in recent session. During the trading, the value of each share was $16.87, dropping -3.16%. The shares saw high fund-flow as the composite value of all the upticks was $12.03 million and the total value of all the downticks was a mere $10.26 million. The net money flow was seen at $1.76 million and the up/down ratio was measured at 1.17. On a weekly basis the shares of the shares have recorded a change of -5.75%.The block trade which occurred today had $0.16 million in upticks and $0.5 million in downticks with the up/down ratio climbing to 0.33. $-0.34 million was the net money flow of the block transaction.
The stock has recorded a 20-day Moving Average of 8.31% and the 50-Day Moving Average is 3.66%. The company shares have dropped 48.81% in the past 52 Weeks. On July 23, 2015 The shares registered one year high of $35.97 and one year low was seen on October 22, 2015 at $10.26. The 50-day moving average is $16.87 and the 200 day moving average is recorded at $18.78. S&P 500 has rallied 1.93% during the last 52-weeks.
Relypsa (NASDAQ:RLYP): The stock opened at $17.54 on Tuesday but the bulls could not build on the opening and the stock topped out at $17.55 for the day. The stock traded down to $16.02 during the day, due to lack of any buying support eventually closed down at $17.00 with a loss of -2.41% for the day. The stock had closed at $17.42 on the previous day. The total traded volume was 3,394,361 shares.
Currently the company Insiders own 4.2% of Relypsa shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -34.03% . Institutional Investors own 81.43% of Relypsa shares. During last six month period, the net percent change held by insiders has seen a change of 71.72%. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Torley Helen, director of Relypsa Inc, had unloaded 1,013 shares at an average price of $19.32 in a transaction dated on June 7, 2016. The total value of the transaction was worth $19,571.
Relypsa, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The Companys lead product candidate, Patiromer for Oral Suspension (Patiromer FOS) is for the treatment of hyperkalemia, a life-threatening condition defined as abnormally elevated levels of potassium in the blood. Its New Drug Application (NDA) for Patiromer FOS was accepted for filing by the United States Food and Drug Administration, or FDA. The Companys NDA is supported by a clinical development program consisting of eight clinical trials: three Phase I trials, four Phase II trials and one two-part Phase III trial conducted under a Special Protocol Assessment, or SPA. The active ingredient is a cross-linked polymeric bead with a calcium containing counterion. The Company has the global royalty-free commercialization rights to Patiromer FOS.